共 149 条
[1]
Bello CL(2009)Electrocardiographic characterization of the QTc interval in patients with advanced solid tumors: pharmacokinetic- pharmacodynamic evaluation of sunitinib Clin Cancer Res 15 7045-7052
[2]
Mulay M(2005)Risk factors for prolonged QTc among US adults: Third National Health and Nutrition Examination Survey Eur J Cardiovasc Prev Rehabil 12 363-368
[3]
Huang X(2008)Drug-induced QTc interval prolongation: a proposal towards an efficient and safe anticancer drug development Eur J Cancer 44 494-500
[4]
Patyna S(2008)QTc prolongation and/or oncology drug development: who's in danger? Eur J Cancer 44 486-487
[5]
Dinolfo M(2012)Evaluation of cardiac safety of lapatinib therapy for ErbB2-positive metastatic breast cancer: a single center experience Med Oncol 29 3232-3239
[6]
Levine S(2013)Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes Toxicol Appl Pharmacol 272 245-255
[7]
Van Vugt A(2013)Blocking of the human ether-a-go-go-related gene channel by imatinib mesylate Biol Pharm Bull 36 268-275
[8]
Toh M(2003)Torsade de pointes Curr Opin Cardiol 18 6-13
[9]
Baum C(2009)Cardiac ion channels Circ Arrhythm Electrophysiol 2 185-194
[10]
Rosen L(2013)A randomized, double-blind, placebo-controlled study to evaluate the effect of repeated oral doses of pazopanib on cardiac conduction in patients with solid tumors Cancer Chemother Pharmacol 71 565-573